RxDoctor Payments Data

Josephine Vu

Family · Downey, CANPI 1790256436

Payments from drug & device makers

$12,829in general payments, 2019–2025

Across 661 payments — averaging $19.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$3K
  • Amgen$1K
  • Novo Nordisk$914
  • Insulet Corporation$772
  • Boehringer Ingelheim$691
  • AstraZeneca$558
  • plus $6K from 39 others

What the payments were for

  • Food & beverage$12,63698%
  • Education$1932%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,829 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$26,801
Medicare patients
112
Services billed
278

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide290$501,369
TrulicityDulaglutide236$346,122
MounjaroTirzepatide122$177,318
JardianceEmpagliflozin111$135,336
JanuviaSitagliptin Phosphate40$56,242
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog28$36,439
FarxigaDapagliflozin Propanediol36$34,735
Evenity (2 Syringes)Romosozumab-Aqqg11$28,518
RybelsusSemaglutide15$19,287
TradjentaLinagliptin16$17,899
Fiasp FlextouchInsulin Aspart (Niacinamide)27$16,689
Repatha SureclickEvolocumab11$16,638
Tresiba Flextouch U-100Insulin Degludec11$15,871
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog41$14,890
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/712$13,091

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro$2,585$532,132403 claims
Novo NordiskOzempic, Rybelsus$914$520,656305 claims
Boehringer IngelheimJardiance, Tradjenta$691$153,235127 claims
MerckJanuvia$92$56,24240 claims
AstraZenecaFarxiga$558$34,73536 claims
AmgenEvenity (2 Syringes)$1,267$28,51811 claims
AbbVieSynthroid$143$2,05729 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,634 family providers in California.

Other family in Downey

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →